Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

General Motors

Micron Technology

Multibillionaire investors are buying stocks at a discount. But they're selling some, too.

3 Stocks the World's Smartest Investors Are Selling

BMY stock is up 21% this year. That's impressive compared to the market as a whole, which has entered bear territory, and it has room to grow.

Best Stocks for 2022: Bristol-Myers Squibb

Apollo Global Management

Booking Hlds

Mr. Cooper Group Inc

Warner Bros Discovery Inc

Alphabet

6 stocks hedge funds love in a recession, including the top 3 holdings from Michael Burry and Leon Cooperman. The post 6 Stocks Hedge Funds Love in a Recession appeared first on InvestorPlace.

6 Stocks Hedge Funds Love in a Recession

Turning Point Therapeutics

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Turning Point Therapeutics, Inc. (NasdaqGS: TPTX) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Turning Point will receive only $76.00 in cash for each share of Turning Point that they own. KSF is seeking to determine whether this consideration and the proces

TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX

AbbVie

Vertex Pharmaceuticals

3 Stocks You Can Buy and Hold for Decades

bluebird bio

Bristol Myers Squibb and Bluebird Bio have drugs in their pipelines that could soon earn FDA approval.

2 Biotech Stocks That Could Soar in the Third Quarter

Domino's Pizza

Eli Lilly

Although Wall Street is hurting right now, not all S&P 500 stocks are getting thrashed. And these beauties are getting ready to break out.

5 S&P 500 Stocks Ready to Break Out

Healthcare is the one sector that has everything an investor needs to navigate the market uncertainty, says Virtus Investment Partners' Joe Terranova. “XLV” is down nearly 10% year-to-date.

Here's one sector that offers ‘offense, defense, growth and value'

Late last year, BMY broke out of a long-term range, and that break out is continuing. BMY stalled for the last few months, but its recent strong activity indicates a probable return to outperforming the second half of 2022.

Bristol-Myers Is Melting-Up Again

Johnson & Johnson

Merck

Pfizer

Seagen

Sanofi

AstraZeneca

Novartis

Roche Holding AG

Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.

Investors Need Not Be Alarmed by Drug Patent Expirations

BMY shares were stagnant for nearly 5 years before gaining ~30% across the past 6 months. Celgene acquisition added $15bn per annum to top line, but more importantly, a pipeline of approvable assets.

Bristol-Myers Squibb: Annual Mid Single-Digit Growth Equals Incremental Upside

Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.

Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion

Chevron

Exxon Mobil

All of the top 10 stocks that have gained 20% or more this year are in these two sectors.

The 2 Best Sectors to Invest in Right Now

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. FDA Approves BMS's CAR T Cell Therapy Breyanzi for Use After One Prior Therapy for Relapsed or Refractory Large B-cell Lymphoma

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

A U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co of delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought for $80.3 billion in 2019.

Bristol Myers must face $6.4 billion lawsuit over delayed cancer drug

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) today announced new post-hoc analyses from the Zeposia (ozanimod) Phase 3 DAYBREAK open-label extension (OLE) and Phase 3 SUNBEAM trials, showing early Zeposia use demonstrated cognitive benefits in people with relapsing multiple sclerosis (MS), with the greatest effect seen in people with high thalamic volume (TV), supporting an association between preserved brain volume (BV) and improved long-term cognitive outcomes. These data

Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) today announced new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) from the ongoing Phase 3 DAYBREAK open-label extension (OLE) study in relapsing multiple sclerosis. For participants who showed no evidence of recent COVID-19 infection, results showed seroconversion occurred in 100% (80/80) and 62% (18/29) of fully vaccinated mRNA and non-mRNA vaccine recipients, respectively. These data are to

New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)

British American Tobacco

FedEx

These stocks offer dividend yields ranging from 2% to an astronomical 7.1%.

3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist

The EMA validates Bristol Myers' (BMY) type II variation application for the label expansion of Breyanzi for treating relapsed/refractory large B-cell lymphoma after first-line therapy.

Bristol Myers' (BMY) Breyanzi sBLA Receives EMA Validation

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Bcell--European Medicines Agency Validates BMS's Application for CAR T Cell Therapy Breyanzi....

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy

Royalty Pharma

Verizon

Wells Fargo

One of Berkshire Hathaway's longest-held stocks was given the heave-ho in the first quarter.

5 Stocks Warren Buffett Has Aggressively Sold Since 2022 Began

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022. Dr. Bhatt will serve as a member of the Science & Technology Committee of the Board of Directors. “We are pleased to welcome Dr. Deepak L. Bhatt to our Board of Directors,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. “Through his role as a physician and leading r

Bristol Myers Squibb Elects Deepak L. Bhatt, M.D.

Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 43rd Annual Global Healthcare Conference June 15, 2022 12:20 PM ET CorporateParticipants Adam Lenkowsky - Senior Vice President and General Manager, U.S. Commercialization ConferenceCall Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, good morning, everybody. This is the place to be obviously with Pfizer and now with Bristol.

Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs 43rd Annual Global Healthcare Conference

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.

Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?

Broadcom

Caterpillar

McDonald's

Altria

Procter & Gamble

Blue-Chip stocks are particularly attractive in volatile times like now. These picks include a strong dividend as well.

News for Bristol-Myers Stock (BMY)